Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response


Muckenhuber A., Berger A. K. , Schlitter A. M. , Steiger K., Konukiewitz B., Trumpp A., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.24, ss.351-359, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 24 Konu: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1158/1078-0432.ccr-17-2180
  • Dergi Adı: CLINICAL CANCER RESEARCH
  • Sayfa Sayıları: ss.351-359

Özet

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis and poor therapeutic response to current chemotherapy regimens in unselected patient populations. Recently, it has been shown that PDAC may be stratified into functionally and therapeutically relevant molecular subgroups and that some of these subtypes can be recapitulated by IHC for KRT81 [quasi-mesenchymal (QM)/squamous/basal-like] and HNF1A (non-QM, overlap with exocrine/ADEX subtype).